Le Lézard
Classified in: Health
Subject: SVY

Global Type 2 Diabetes Epidemiology and Patient Flow Analysis - 2017


LONDON, Nov. 16, 2017 /PRNewswire/ -- Fore Pharma announced the results of its Type 2 Diabetes patients study in a new report 'Global Type 2 Diabetes Epidemiology and Patient Flow Analysis - 2017'.

Download the full report: https://www.reportbuyer.com/product/3895278

The report provides insights into Type 2 Diabetes epidemiology, Type 2 Diabetes diagnosed patients, and Type 2 Diabetes treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Type 2 Diabetes derived from epidemiological analysis, percentage of patients diagnosed with Type 2 Diabetes, and percentage of patients treated with a therapy.

The study helps executives estimate Type 2 Diabetes market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Type 2 Diabetes prevalence, Type 2 Diabetes diagnosis rate, and Type 2 Diabetes treatment rate for the period 2016 - 2025. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.

Key Features of the Report:
- Type 2 Diabetes Patient Flow
- Type 2 Diabetes Prevalence
- Type 2 Diabetes Diagnosed Patients
- Type 2 Diabetes Treated Patients

Download the full report: https://www.reportbuyer.com/product/3895278

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 06:30
Boston Scientific Announces Results for First Quarter 2024
Boston Scientific Corporation generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior...

at 06:28
Pharma Parenteral Packaging Market in the North America is Anticipated to Register a Significant Share in Revenue to 2031 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Pharma Parenteral Packaging Market ? By Drug Type (Small Molecules, Biologics, Vaccines, Biosimilars, & Others), By Product Type (Bottles, Ampoules,...

at 06:15
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Patients at the Two-Year Milestone8.08 Points...

at 06:10
Thermo Fisher Scientific to Host Investor Day
Thermo Fisher Scientific Inc. , the world leader in serving science, will hold its 2024 Investor Day on Thursday, September 19, starting at 9:00 a.m. (ET) in New York City. The format will feature presentations by members of Thermo Fisher...

at 06:05
Thermo Fisher Scientific Reports First Quarter 2024 Results
Thermo Fisher Scientific Inc. , the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Highlights First quarter revenue was $10.34 billion. First quarter GAAP...

at 06:05
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
Biodesix, Inc. , a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix's...

More news about Health...


News published on and distributed by: